Marinomed Biotech AG · VIE:MARI
Marinomed Biotech — Investor Presentation (June 2022)
21 slides from Marinomed Biotech's investor presentation, June 2022
Slide 1: Corporate Presentation
Corporate Presentation June 2022
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Marinomed investment highlights
Marinomed investment highlights Transforming lives of people suffering from diseases with limited or no treatment options • Management team with 100+ years of experience in biopharma with track record spanning from invention to commercialization • Short term growth perspective with existing product
Slide 4: Marinomed management and ownership
Marinomed management and ownership Total number of shares 13.7% 1,496,287 Left to right: 8.4% Pascal Schmidt, CFO; Eva Prieschl-Grassauer, CSO and co-founder; Cornelia Kutzer, CBO, Acropora Beteiligungs GmbH Andreas Grassauer, CEO and co-founder 8.1% Dr. Hermann Unger 61.7% DI Dr. Andreas Grassauer
Slide 5: Marinomed at a glance
Marinomed at a glance Unmet medical need Lean, public company Immunology: with track record of Company Rare disease: herpetic stromal keratitis1 successfully inventing, Founded Virology: partnering and in 2006 no broadband antiviral marketing products Marketed products treatment for viral pneumonia
Slide 6: Strategic horizons for Marinomed
Strategic horizons for Marinomed Long-term vision Strategy 2025f Leading biopharma company for rare autoreactive immune disorders and Move towards higher valued viral infectious diseases Rx drugs addressing unmet Short-term medical needs Maximise current OTC portfolio Succeed with next-generation
Slide 7: Marinomed has built a proven track record
Marinomed has built a proven track record Successes in the therapeutic areas Immunology Virology • First aqueous steroid solution, all other major • Discovery of the efficacy of Carragelose against competitors are suspensions respiratory viruses • Performance of a series of clinical studies to suppo
Slide 8: Strategy 2025
Strategy 2025 Creating sustainable value for patients and shareholders High relevance High attractiveness High chance of partnering © Marinomed Biotech AG 8
Slide 9: Strong pipeline – still more to come
Strong pipeline – still more to come Growth potential to pursue Solid base to build on © Marinomed Biotech AG 9
Slide 10: Fighting against visual impact
Fighting against visual impact Rare disease herpetic stromal keratitis (HSK) caused by ocular herpes virus infection Prevalence Unmet medical need Herpesvirus induced keratitis • >90% of the global population has a In the developed world without China latent infection with HSV-1 by the age of sixty1
Slide 11: Tacrolimus
Tacrolimus Best in class macrolide immunosuppressant – a substance that could benefit so many more patients if solubilized • Macrolide calcineurin inhibitor Tacrosolv is a Marinosolv-enabled formulation of Tacrolimus1 • Practically insoluble in water Strongly increased bioavailability demonstrated1:
Slide 12: Tacrosolv
Tacrosolv Fully solubilized macrolide immunosuppressant – validated in clinical phase II trial TOSS* day 8 % reduction compared to day 1 Rationale for the use of Tacrosolv 6 Placebo Verum • Clinical proof of concept in model 5 0 indication allergic conjunctivitis showing anti-inflammatory activity1
Slide 13: Autoimmune gastritis (AIG)
Autoimmune gastritis (AIG) Chronic inflammatory disorder of stomach lining without specific anti- inflammatory treatment available What is AIG? Standard of care Prevalence • Inflammation of gastric mucosa • No effective anti-inflammatory • Highly variable due to different due to an autoimmune reacti
Slide 14: Fighting against viral pneumonia
Fighting against viral pneumonia Need for improved treatments targeting different respiratory virus families Evolving viral strains due to Infectious viral pathogen in Pandemic Endemic constant mutations1 hospitalized patients2 2,10% 8,10% 20,20% Global consecutive Regional seasonal 8,20% waves up t
Slide 15: INHALeeN
INHALeeN Broad-spectrum inhalable antiviral product combining at least two different mode of actions for optimal treatment of viral pneumonia Virus-blocking Efficacy of the combination of IC and Rationale for the use of iota- Virus type activity zanamivir against influenza H7N7 in a carrageenan (IC)
Slide 16: Business model
Business model Lean structure focused on creating sustainable values Collaborations with Research Revenue from and • Upfront • Academia Partnering • Milestones • Innovative partners invention • Royalties • KOLs Generation of IP Partly outsourcing to Pre- • CROs clinical Early • Planning of clinical
Slide 17: Market potential
Market potential Marinomed tapping into high value markets Immunology – Tacrosolv HSK target population1 Virology – INHALeeN population at-risk2 80 400 people in thousands 60 300 people in millions 40 200 20 100 0 0 United States Europe 5 Japan China United States Europe 5 Japan China Increased risk
Slide 18: Sustainability
Sustainability Marinomed contributes to sustainability goals and adheres to ESG • Develop products containing less API – for patients and for the environment • Use more renewable energy • Promote environmentally friendly supply chains ENVIRONMENT • Therapies for people living with diseases with limi
Slide 19: Financial performance
Financial performance Solid business as basis for future growth Historical performance (revenues and EBIT) Key growth drivers 11.6* Virology 8.1 4.7 6.1 Carragelose business Revenues • Established in >40 countries with strong distribution and marketing partners EBIT • Strong revenue generation, EBIT
Slide 20: Timeline 2022/2023
Timeline 2022/2023 News flow / milestones • January – Strengthening business development through new CBO Cornelia Kutzer • February – Draw down of €6m EIB financing tranche News flow to • April – New agreement with Hanmi for marketing of Carragelose in South Korea date • April – Publication of stron
Slide 21: The Marinomed story
The Marinomed story Transforming lives of people suffering from diseases with limited or no treatment options • Highly experienced management • Short term and long-term growth perspective • Therapies for diseases with unmet medical need • Lean and efficient business model • Sustainable therapies © M
Marinomed Biotech — Investor Presentation (June 2022) on 6ix